Author:
Avdeeva A. S.,Cherkasova M. V.,Nasonov E. L.
Abstract
Abstract
The objective of the study was to find a potential relationship between ACPAs and disease activity, bone destruction, and ACPA responses to various therapeutic regimens. The study included 232 patients with rheumatoid arthritis (RA); 90 patients had early RA, and 142 patients had an advanced stage of the disease. 77 (85.6%) patients with early RA were highly positive for anti-CCP, and 29 (70.7%) patients were highly positive for anti-MCV. A positive correlation was found between anti-MCV and DAS28 (r = 0.4; p = 0.04). As for advanced RA, 78 (80.4%) patients were high-positive for anti-CCP, and 70 (79.5%) were high-positive for anti-MCV. There was a positive correlation between anti-MCV concentration and SDAI (r = 0.4; p = 0.02), as well as CDAI (r = 0.4; p = 0.02). No significant correlations were found between the anti-CCP levels and activity indices, anti-CCP and acute-phase parameters in both early and advanced RA groups. Higher total Sharp scores (96.5 (65.0–122.0)) were found in pts highl-positive for anti-MCV (n = 79), compared to low-positive/negative (n = 27) patients (57.0 (31.0–88.0); p < 0.05). Anti-MCV levels dropped significantly in pts on rituximab and tocilizumab therapy at weeks 12 and 24 after initiation of treatment, while high anti-CCP concentration persisted throughout the treatment. Anti-MCV levels correlated with inflammatory activity and development of bone destruction and decreased in pts on treatment. Anti-CCP was less responsive and showed minor changes during treatment; therefore, its thorough monitoring was not feasible.
Subject
General Chemistry,Biochemistry,General Medicine,Biophysics
Reference40 articles.
1. Nasonov, E.L., Problems of rheumatoid arthritis immunopathology: evolution of the disease, Nauchno-Prakt.
Revmatol., 2017, vol. 55, no. 3, pp. 277–294.
2. Cantagrel, A. and Degboe, Y., New autoantibodies associated with rheumatoid arthritis recognize posttranslationally modified self-protein, Joint Bone Spain, 2016, vol. 83, pp. 11–17.
3. Mastrangelo, A., Colasanti, T., Barbati, C., et al., The role of posttranslational protein modifications in rheumatological diseases: focus on rheumatoid arthritis, J. Immunol. Res., 2015.
4. Darrah, E. and Andrade, F., Citrullination, and carbamylation, and malondialdehyde-acetaldehyde! Oh My! Entering the forest of autoantigen modifications in rheumatoid arthritis, Arthritis Rheum., 2015, vol. 67, pp. 604–608.
5. Nasonov, E.L. and Aleksandrova, E.N., Sovremennye standarty laboratornoi diagnostiki revmaticheskikh zabolevanii: klinicheskie rekomendatsii (Modern Standards for Laboratory Diagnosis of Rheumatic Diseases: Clinical Guidelines), Moscow: ZAO BioKhimMak, 2006.